SR 121566
inhibits heparin-induced platelet aggregation in plasma from patients with heparin-induced thrombocytopenia; SR 121787 is prodrug of this corresponding diacid SR 121566;
Also Known As:
SR 121566A; SR-121566A; SR121566
Networked: 4
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Thrombosis (Thrombus)
02/01/2000
- " On rabbits pre-treated with aspirin (10 mg/kg, i.v.), a bolus injection of SR121566 produced a strong reversal of thrombosis compared with the effect obtained on rabbits treated with SR121566 alone. " 02/01/2000
- " SR121566 (3 mg/kg, i.v.), a new selective antagonist of the GP-IIb/IIIa complex inhibited thrombus formation which occurred following electrical stimulation of the carotid artery of rabbits. " 09/01/1997
- " After oral administration of SR 121787, the prodrug of SR 121566, rabbit platelet aggregation ex vivo was inhibited in a dose-dependent manner [median effective dose (ED50) for ADP- arachidonic acid (AA)- and collagen-induced aggregation 2 h after gavage, 2.3 +/- 0.3, 6.1 +/- 0.9, and 2.5 +/- 0.4 mg/kg], a 58% inhibition of ADP-induced platelet aggregation being still observed 6 h after single oral treatment with 20 mg/kg. In an arteriovenous-shunt model, oral administration of SR 121787 resulted in a dose-dependent inhibition of thrombus growth (ED50, 10.4 +/- 0.8 mg/kg). "
|
2. | Thrombocytopenia (Thrombopenia)
|
3. | Hemorrhage
|
|
Related Drugs and Biologics
Related Therapies and Procedures